Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Erlotinib + Gemcitabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Erlotinib||Tarceva||CP358774||EGFR Inhibitor (Pan) 55 EGFR Inhibitor 1st gen 3||Tarceva (erlotinib) is a first-generation EGFR inhibitor that blocks EGFR signaling, potentially leading to inhibition of tumor growth (PMID: 30069756). Tarceva (erlotinib) is FDA approved for use in patients with non-small cell lung cancer harboring EGFR exon 19 deletions and/or EGFR L858R, and in combination with gemcitabine for patients with locally advanced, unresectable, or metastatic pancreatic cancer (FDA.gov).|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 14||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CBL dec exp||pancreatic ductal carcinoma||predicted - sensitive||Erlotinib + Gemcitabine||Preclinical - Cell line xenograft||Emerging||In a preclinical study, addition of Tarceva (erlotinib) overcame Gemzar (gemcitabine)-resistance in pancreatic ductal carcinoma cell lines with reduced Cbl expression via shRNA, resulted in decreased viability in cell culture and reduced tumor growth in cell line xenograft models (PMID: 25348515).||25348515|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02154737||Phase I||Erlotinib + Gemcitabine||Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer||Completed||USA||0|
|NCT01013649||Phase II||Erlotinib + Gemcitabine Gemcitabine||Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery||Active, not recruiting||USA | CAN | BEL||1|